Mallinckrodt (NYSE:MNK) – Analysts at Cantor Fitzgerald dropped their FY2018 earnings per share (EPS) estimates for Mallinckrodt in a research note issued to investors on Tuesday, April 3rd. Cantor Fitzgerald analyst L. Chen now expects that the company will earn $6.03 per share for the year, down from their prior forecast of $6.04. Cantor Fitzgerald has a “Buy” rating and a $42.00 price objective on the stock.
A number of other equities analysts have also issued reports on MNK. Barclays set a $23.00 price target on Mallinckrodt and gave the stock a “hold” rating in a report on Tuesday, December 12th. Wells Fargo reissued a “hold” rating on shares of Mallinckrodt in a report on Tuesday, December 26th. Canaccord Genuity set a $24.00 price target on Mallinckrodt and gave the stock a “hold” rating in a report on Tuesday, December 26th. Goldman Sachs reissued a “hold” rating on shares of Mallinckrodt in a report on Tuesday, December 26th. Finally, ValuEngine lowered Mallinckrodt from a “buy” rating to a “hold” rating in a report on Sunday, December 31st. Three research analysts have rated the stock with a sell rating, eleven have issued a hold rating and six have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $35.00.
NYSE MNK opened at $14.48 on Friday. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.85 and a current ratio of 2.18. Mallinckrodt has a 52-week low of $13.64 and a 52-week high of $49.12. The stock has a market cap of $1,271.08, a P/E ratio of 1.93, a P/E/G ratio of 0.37 and a beta of 1.12.
Mallinckrodt (NYSE:MNK) last issued its quarterly earnings data on Tuesday, February 27th. The company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.72 by $0.29. The company had revenue of $792.30 million for the quarter, compared to analyst estimates of $769.91 million. Mallinckrodt had a return on equity of 13.43% and a net margin of 66.25%. The business’s quarterly revenue was down 4.5% compared to the same quarter last year. During the same quarter last year, the company posted $1.91 earnings per share.
A number of large investors have recently made changes to their positions in MNK. State of Alaska Department of Revenue acquired a new stake in Mallinckrodt in the fourth quarter valued at about $129,000. Amundi Pioneer Asset Management Inc. acquired a new stake in Mallinckrodt in the fourth quarter valued at about $190,000. Shelton Capital Management acquired a new stake in Mallinckrodt in the third quarter valued at about $205,000. Sciencast Management LP acquired a new stake in Mallinckrodt in the fourth quarter valued at about $210,000. Finally, CIBC World Markets Inc. acquired a new stake in Mallinckrodt in the fourth quarter valued at about $231,000. Hedge funds and other institutional investors own 97.38% of the company’s stock.
WARNING: This news story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/07/fy2018-eps-estimates-for-mallinckrodt-mnk-lowered-by-cantor-fitzgerald.html.
Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.
Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.